{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit not estimable","groupId":"OG000","lowerLimit":"22.7","upperLimit":"NA","value":"41.2"},{"comment":"The median was not reached because of an insufficient number of events","groupId":"OG001","lowerLimit":"0.6","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"OS is defined as the time from first dosing date to the date of death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received treatment with Elotuzumab in combination with Pomalidomide and low-dose Dexamethasone in a 28 day cycle.","id":"OG000","title":"EPd Cohort"},{"description":"Participants received Elotuzumab in combination with Nivolumab in a 28-day cycle.","id":"OG001","title":"EN Cohort"}],"paramType":"MEDIAN","populationDescription":"All treated participants","reportingStatus":"POSTED","timeFrame":"From first dose to study completion date (up to approximately 50 months)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}